Project Grant HT94252510055
Award Date
3/1/25
Completion Date
2/29/28
Dollars Obligated
$1.8M
Federal Agency
Defense Health Agency
Federal Grant Program
12.420
Assistance Type
Project Grant
Place of Performance
Boston, MA 02115, USA
Similar Awards
The Department of the Army Medical Command awarded a $1,074,000 Project Grant under the Military Medical Research and Development (CFDA 12.420) program to Brigham & Women's Hospital Inc., a subsidiary of Partners Healthcare System Incorporated, to produce cultured red blood cells for sickle cell disease patient support. The grant period runs from June 1, 2025 to May 31, 2029. Brigham & Women's Hospital Inc. is a prominent academic medical center and research institution in Boston,...
The federal Project Grant award in the amount of $617,367 was provided by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program. The award is being used by the Children's Hospital Corporation, doing business as Boston Children's Hospital, to conduct research on "BASE EDITING TO IMPROVE CONDITIONING AND TRANSPLANT OF BONE MARROW FAILURE PATIENTS". The research project aims to leverage innovative gene editing techniques to enhance the...
This $1,428,720 Project Grant, awarded by the Defense Health Agency (DHA) under the Military Medical Research and Development (CFDA 12.420) federal grant program, supports an investigation of menin/KMT2A protein degradation for the treatment of myeloid neoplasms. The project will be conducted by Brigham & Women's Hospital, a prominent academic medical center and research institution in Boston, Massachusetts, that is part of the Mass General Brigham healthcare system. The research aims to...
The federal Project Grant award of $772,626.00 was provided by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program to Brigham & Women's Hospital Inc., a research subsidiary of Partners Healthcare System Incorporated. The award will fund preclinical validation of gene therapy in mouse models of tuberous sclerosis complex (TSC) and lymphangioleiomyomatosis (LAM) over a performance period from August 1, 2025 to July 31, 2028. This research aims to...
The Department of Defense's Military Medical Research and Development program (CFDA 12.420) awarded a $1,416,000 Project Grant to The Children's Hospital Corporation (Boston Children's Hospital), a non-profit teaching hospital and research center affiliated with Harvard Medical School. The grant, titled "IND-ENABLING STUDIES OF POLYMERASE INHIBITORS FOR BMF DUE TO TELOMERE EXHAUSTION", will support a 2-year research project from Sep 1, 2023 to Aug 31, 2025. Through this funding, Boston...
This $1,683,194 federal Project Grant award was provided by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program. The grant supports Brigham & Women's Hospital Inc., a Harvard-affiliated academic medical center, in conducting research on the role of the glycome in identifying biomarkers and understanding the molecular pathogenesis of tuberous sclerosis complex (TSC). The 3-year grant, running from August 2025 to July 2028, will fund advanced...
The U.S. Department of the Army Medical Command has awarded a $577,383.00 Project Grant to The Children's Hospital Corporation, doing business as Boston Children's Hospital, under the Military Medical Research and Development (CFDA 12.420) federal grant program. This grant, with a performance period from September 1, 2024 to August 31, 2027, will support the hospital's research to develop base editing techniques to improve conditioning and transplantation of bone marrow failure patients. As a...
The federal Project Grant award for $236,072 from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) supports research to evaluate the efficacy of novel B7-H3 antibodies in tuberous sclerosis complex (TSC). The awardee, Brigham & Women's Hospital Inc., a subsidiary of Partners Healthcare System, will conduct this biomedical research project over a 2-year period from August 1, 2024 to July 31, 2026. As a leading academic medical center, Brigham...
This $1,016,449.00 Project Grant award was issued by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) federal grant program. The grant supports single-cell studies of immune-mediated injury and immunoregulation in human vascular composite allograft (VCA) rejection, with a performance period from August 1, 2024 to July 31, 2027. The award was granted to Brigham & Women's Hospital Inc., a prominent academic medical center and research institution in...
The Defense Health Agency awarded a $682,266 Project Grant to Brigham & Women's Hospital Inc. under the Military Medical Research and Development program (CFDA 12.420) on May 15, 2024. The grant supports research to develop targeted endothelial cell-derived extracellular vesicle nanoparticles for immunotherapy against brain cancer, with a performance period ending on May 14, 2026. As a subsidiary of Partners Healthcare System Incorporated, Brigham & Women's Hospital has extensive...